Skip to main content

Cocrystal Pharma, Inc.

For the period ended Jun 30, 2026. Filed Aug 13, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 13, 2026

COCP$1.04+4.0%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits

Cover page

Show cover page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30,2026

OR

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number:001-38418

COCRYSTAL PHARMA, INC.

(Exact name of registrant as specified in its charter)

Delaware35-2528215
(State or Other Jurisdiction of(I.R.S. Employer
Incorporation or Organization)Identification No.)
19805 North Creek Parkway Bothell, WA98011
(Address of Principal Executive Office)(Zip Code)

Registrant’s telephone number, including area code:877-262-7123

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Sec.232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer☐Accelerated filer☐
Non-accelerated filer☒Smaller reporting company☒
Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No☒

Securities registered pursuant to Section 12(b) of the Act:

Title of Each ClassTrading Symbol(s)Name of each exchange on which registered
Common StockCOCPThe Nasdaq Stock Market LLC (The Nasdaq Capital Market)

As of August 13, 2026, the number of outstanding shares of the registrant’s common stock, par value $0.001 per share, was approximately 19,263,200.

COCRYSTAL PHARMA, INC.

FORM 10-Q FOR THE QUARTER ENDED JUNE 30, 2026

INDEX

Part I - FINANCIAL INFORMATION
Item 1.
Condensed Consolidated Balance SheetsF-1
Condensed Consolidated Statements of OperationsF-2
Condensed Consolidated Statements of Stockholders’ EquityF-3
Condensed Consolidated Statements of Cash FlowsF-4
Notes to the Condensed Consolidated Financial StatementsF-5
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations3
Item 3. Quantitative and Qualitative Disclosures About Market Risk10
Item 4. Controls and Procedures10
Part II - OTHER INFORMATION
Item 1. Legal Proceedings11
Item 1. A. Risk Factors11
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds11
Item 3. Defaults Upon Senior Securities11
Item 4. Mine Safety Disclosures11
Item 5. Other Information11
Item 6. Exhibits11
SIGNATURES12
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.